In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1917-1926

  Wosikowski, Katja ^a,c   Biedermann, Elfi ^a   Rattel, Benno ^a,c   Breiter, Norbert ^a   Jank, Peter ^a   Löser, Roland ^a   Jansen, Gerrit ^b   Peters, Godefridus J ^b  

^a Pharmacology Department   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GPC Biotech AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SERUM ALBUMIN; METHOTREXATE; METHYLAMINE; RECEPTOR; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG UPTAKE; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DIVISION; HUMANS; MALE; METHOTREXATE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; SERUM ALBUMIN; THYMIDYLATE SYNTHASE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0038327602     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Peters, T. Serum albumin. Adv. Protein Chem., 37: 161-245, 1986.
2. Allegra, C. J., and Grem, J. L. Antimetabolites. In: V. T. DeVita Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, pp. 432-452. NewYork: Lippincott-Raven Publishers, 1997.
3. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D., Torchilin, V., and Jain, R. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 55: 3752-3756, 1995.
4. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Controlled Release, 65: 271-284, 2000.
5. Matsumura, Y., and Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46: 6387-6392, 1986.
6. Sinn, H., Schrenk, H. H., Friedrich, E. A., Schilling, U., and MaierBorst, W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int. J. Radiat. Appl. Instrum. B, 17: 819-827, 1990.
7. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Stewart, J. C., Hartung, G., Maier-Borst, W., and Heene, D. L. Plasma protein (albumin) catabolism by the tumor itself: implications for tumor metabolism and the genesis of cachexia. Crit. Rev. Oncol. Hematol., 26: 77-100, 1997.
8. Sett, R., Sarkar, H. S., and Das, P. K. Pharmacokinetics and biodistribution of methotrexate conjugated to mannosyl human serum albumin. J. Antimicrob. Chemother., 31: 151-159, 1993.
9. Halbert, G. W., and Florence, A. T. Physicochemical characterization of methotrexate-bovine serum albumin conjugates. J. Pharm. Pharmacol., 41: 222-226, 1989.
10. Slavik, K., Motycka, K., and Bostik, J. The use of protein as a carrier of methotrexate for experimental cancer chemotherapy. II. Chemotherapy of Gardner lymphosarcoma with pea seed lectin-methotrexate derivative. Neoplasma, 33: 409-416, 1986.
11. Jacobs, S. A., d'Urso-Scott, M., and Bertino, J. R. Some biochemical and pharmacologic properties of amethopterin-albumin. Ann. N. Y. Acad. Sci., 186: 284-286, 1971.
12. Yoon, E. J., Chang, H. W., Lee, M. G., Lee, H., Park, N. K., and Kin, C. K. Pharmacokinetics of methotrexate after intravenous infusion of methotrexate-rabbit serum albumin conjugate in rabbits. Int. J. Pharmaceutics, 67: 177-184, 1991.
13. Stehle, G., Sinn, H., Wunder, A., Schrenk, H. H., Schutt, S., Maier-Borst, W., and Heene, D. L. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats. Anticancer Drugs, 8: 677-685, 1997.
14. Hartung, G., Stehle. G., Sinn, H., Wunder, A., Schrenk, H. H., Heeger, S., Kranzle, M. E. L., Frei, E., Fiebig, H. H., Heene, D. L., Maier-Borst, W., and Queisser, W. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I study group of the Association for Medical Oncology of the German Cancer Society. Clin. Cancer Res., 5: 753-759, 1999.
15. Rosowsky, A., Lazarus, H., Yuan, G. C., Beltz, W. R., Mangini, L., Abelson, H. T., Modest, E. J., Frei, E., III. Effects of methotrexate esters and other lipophilic antifolates on methotrexate-resistant human leukemic lymphoblasts. Biochem. Pharmacol., 29: 648-652, 1980.
16. Jansen, G., Westerhof, G. R., Jarmuszewski, M. J. A., Kathmann, I., Rijksen, G., and Schornagel, J. H. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. J. Biol. Chem., 265: 18272-18277, 1990.
17. Jansen, G., Mauritz, R., Drori, S., Specher, H., Kathmann, I., Bunni, M. A., Priest, D. G., Noordhuis, P., Schornagel, J. H., Pinedo, H. M., Peters, G. J., and Assaraf, Y. G. A structrually altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem., 273: 30189-30198, 1998.
18. McCloskey, D. E., McGuire, J. J., Russell, C. A., Rowan, B. G., Bertino, J. R., Pizzorno, G., and Mini, E. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J. Biol. Chem., 266: 6181-6187, 1991.
19. Westerhof, G. R., Kathmann, I., Schornagel, J. H., Jackman, A. L., Rosowsky, A., Forsch, R. S., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
20. Westerhof, G. R., Rijnboutt, S., Schornagel, J. H., Pinedo, H. M., Peters, G. J., and Jansen, G. Functional activity of the reduced folate carrier in KB, MA-104, and IGROV-1 cells expressing membrane folate binding protein. Cancer Res., 55: 3795-3802, 1995.
21. Yalowich, J. C., and Kalman, T. I. Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro. Biochem. Pharmacol. 34: 2319-2324, 1985.
22. Mauritz, R., Bekkenk, M., Rots, M. G., Pieters, R., Mini, E., Veerman, A. J. P., Pinedo, H. M., Peters, G. J., and Jansen, G. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia blast cells. Clin. Cancer Res., 4: 2399-2410, 1998.
23. Rots, M. G., Pieters, R., Kaspers, G. J., van Zantwijk, C. H., Noordhuis, P., Mauritz, R., Veerman, A. J., Jansen, G., and Peters, G. J. Differential methotrexate resistance in childhood T- versus common/ preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood, 93: 1067-1074, 1999.
24. de Duve, C., de Barsy, T., Poole, B., Trouet, A., Tulkens, P., and Van Hoof, F. Lysosomotropic agents. Biochem. Pharmacol., 23: 2495-2531, 1974.
25. Poole, B., and Okhuma, S. Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J. Cell Biol., 90: 665-669, 1981.
26. Leamon, C. P., and Low, P. S. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc. Natl. Acad. Sci. USA, 88: 5572-5576, 1991,
27. Fitzpatrick, J. J., and Garnett, M. C. Studies on the mechanism of action of an MTX-HSA-MoAb conjugate. Anti-Cancer Drug Des., 10: 11-24, 1995.
28. Wunder, A., and Stehle, G. Enhanced albumin uptake by rat tumours. Int. J. Oncol., 11: 497-507, 1997.